MathBiology Wins 1st Edition of “Battle Startup in Healthcare” Contest by Paideia & Mater Dei Group

We are thrilled to announce that MathBiology has emerged victorious in the 1st edition of the “Battle Startup in Healthcare,” organized by the Paideia & Mater Dei Group alongside Ventive. Our innovative medical device, designed to revolutionize health diagnostics, has been recognized for its potential to significantly impact the field of prevention and diagnosis.

“Innovation in healthcare, particularly in prevention and diagnostics, is key to offering the best care to people. MathBiology’s device embodies this mission, and we are excited to support its development,” says Alberto De Angelis, Commercial Director and Innovation Manager at Paideia International Hospital and Mater Dei General Hospital in Rome.

On March 25th in Rome, MathBiology was honored for its groundbreaking approach to health technology, winning the prestigious €10,000 prize. Our device, which maps the health status of each organ in a single visit, uses cutting-edge technology to assess the effectiveness of ongoing treatments and detect early health issues, supporting better clinical outcomes.

“This award is a significant validation of our project,” says Alessandro Cascia, CFO and partner at MathBiology. “It’s not only a vote of confidence in our technology but also a step toward bringing our innovative solution to the market to serve people’s health.”

The event, promoted by Paideia & Mater Dei with the support of Ventive, brought together numerous startups, all showcasing promising healthcare innovations. Carolina Grassi, PR & Sales Manager at Ventive, highlighted the importance of such initiatives, saying: “This collaboration between Paideia, Mater Dei, and Ventive has demonstrated the value of innovation in a healthcare sector that often remains tied to traditional models. Paideia’s belief in the power of new technologies was critical in identifying the best proposals.”

MathBiology is proud to be recognized as a leader in healthcare innovation, and we remain committed to pushing the boundaries of technology to improve diagnostics, therapy, and ultimately, patient well-being.